Cargando…
Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma
Drugs that modify the epigenome are powerful tools for treating cancer, but these drugs often have pleiotropic effects, and identifying patients who will benefit from them remains a major clinical challenge. Here we show that medulloblastomas driven by the transcription factor Gfi1 are exquisitely d...
Autores principales: | Lee, Catherine, Rudneva, Vasilisa A., Erkek, Serap, Zapatka, Marc, Chau, Lianne Q., Tacheva-Grigorova, Silvia K., Garancher, Alexandra, Rusert, Jessica M., Aksoy, Ozlem, Lea, Robin, Mohammad, Helai P., Wang, Jianxun, Weiss, William A., Grimes, H. Leighton, Pfister, Stefan M., Northcott, Paul A., Wechsler-Reya, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338772/ https://www.ncbi.nlm.nih.gov/pubmed/30659187 http://dx.doi.org/10.1038/s41467-018-08269-5 |
Ejemplares similares
-
Characterization of G-CSF receptor expression in medulloblastoma
por: Paul, Megan Rose, et al.
Publicado: (2020) -
MBRS-12. A TRANSPOSON MUTAGENESIS SCREEN IDENTIFIES Rreb1 AS A DRIVER FOR GROUP 3 MEDULLOBLASTOMA
por: Masihi, Meher Beigi, et al.
Publicado: (2020) -
LSD1 inhibitors disrupt the GFI1 transcription repressor complex
por: Maiques-Diaz, Alba, et al.
Publicado: (2018) -
Proteomic profiling of high risk medulloblastoma reveals functional biology
por: Staal, Jerome A., et al.
Publicado: (2015) -
OMIC-05. PHOSPHOPROTEOMIC ANALYSIS IDENTIFIES SUBGROUP ENRICHED PATHWAYS AND KINASE SIGNATURES IN MEDULLOBLASTOMA
por: Leskoske, Kristin, et al.
Publicado: (2021)